DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Martin Shkreli - 1 pharma bro - 1 Shkreli - 1 Benjamin Brafman - 1 Brafman - 1 Denise Cote - 1 — - 1 Peluso - 1
Top related locs:
New York California Manhattan
Top related orgs:
Turing Pharmaceuticals AG - 1 pharma - 1 U.S - 1 Circuit - 1 New - 1 Federal Trade Commission - 1 CNBC - 1 FTC - 1

Search resuls for: "Vyera Pharmaceuticals"


4 mentions found


☆ Appeals court upholds 'pharma bro' Martin Shkreli lifetime ban from drug industry
  + stars: | 2024-01-23 | by ( Dan Mangan | ) www.cnbc.com   time to read: +4 min
A federal appeals court Tuesday upheld a lifetime ban on "pharma bro" Martin Shkreli from working in the pharmaceuticals industry as well as an order to pay up to $64.6 million in disgorged profits for blocking competition to the drug Daraprim. His lawyer, Benjamin Brafman, in a statement to CNBC on the appeals court decision, said, "The lifetime ban is too severe." In its eight-page ruling, the appeals court noted that Shkreli argued that Manhattan federal court Judge Denise Cote "abused" her discretion in imposing a lifetime ban on him from the drug business. "The district court found, and Shkreli does not dispute, that Shkreli's illegal scheme was "egregious, deliberate, repetitive, long-running, and ultimately dangerous." "Given his strategic decision in the district court, there is no injustice to Shkreli by us declining to address his new argument."
Persons: Martin Shkreli, pharma bro, Shkreli, Benjamin Brafman, Brafman, Denise Cote, —, Peluso Organizations: Turing Pharmaceuticals AG, pharma, U.S, Circuit, New, Federal Trade Commission, CNBC, FTC, Vyera Pharmaceuticals, Phoenixus, Mr Locations: New York, California, Manhattan
☆ Martin Shkreli-founded drug company files for bankruptcy
  + stars: | 2023-05-10 | by ( Dietrich Knauth | ) www.reuters.com   time to read: +3 min
Vyera said its bankruptcy was the result of declining profits, increased competition for generic drugs, and litigation alleging that Vyera suppressed competition for its most valuable drug, Daraprim. Daraprim is a life-saving anti-parasitic medicine that Shkreli infamously raised the price on by more than 4000% and worked to choke off generic competition for after the company acquired the drug in 2015. Vyera filed a Chapter 11 plan in court on Wednesday, laying out it its intent to repay creditors through asset sales. Vyera said that recently-sold vouchers have fetched prices between $95 million and $120 million in sales that have occurred since 2020. Vyera listed Duane Morris as its largest unsecured creditor in its bankruptcy filing, with a $2.1 million asserted debt.
☆ Convicted Pharma Fraudster Shkreli’s Companies File For Bankruptcy
  + stars: | 2023-05-10 | by ( Alexander Gladstone | ) www.wsj.com   time to read: 1 min
Vyera Pharmaceuticals, the company that Martin Shkreli founded and used to conduct a securities fraud that landed him in prison, filed for bankruptcy Wednesday. Vyera, its Swiss parent company Phoenixus and several affiliates filed for protection in the U.S. Bankruptcy Court in Wilmington, Del. after the reputational harm from Mr. Shkreli’s fraud hampered them from opening bank accounts, commercializing products or raising capital, court papers say. A lawyer who has represented Mr. Shkreli didn’t immediately respond to a request...
☆ FTC asks judge to hold 'pharma bro' Martin Shkreli in contempt of court for forming new drug firm
  + stars: | 2023-01-20 | by ( Dan Mangan | ) www.cnbc.com   time to read: +4 min
The Federal Trade Commission on Friday asked that notorious "pharma bro" Martin Shkreli be held in contempt of court for forming a new drug company in violation of a judge's ban on the convicted fraudster from working in the pharmaceuticals industry. In its court filing Friday, the FTC noted that Shkreli in July announced the formation of a new company, Druglike, "that appears to be involved in the drug industry." The FTC said Shkreli is required by Cote's order to provide the agency with that information. Benjamin Brafman, a lawyer for Shkreli, declined to comment on the FTC filing. Shkreli was driven back to New York from his prison in Pennsylvania by a friend, Edmund Sullivan, who had previously served on the board of Retrophin.
0 next >>
Total: 4